Novo Nordisk Foundation grants DKK 5.5 billion to elevate innovation in Denmark and Europe The Novo Nordisk Foundation has allocated up to DKK 5.5 billion (EUR 736 million) to the BioInnovation Institute (BII), a leading institute for life science and deep tech innovation in Copenhagen. The funding will enable BII to expand its activities into […]
Seasoned executive with extensive board experience across US and European biotechnology companies Brings extensive operational, strategic and transactional expertise as AstronauTx advances its innovative pipeline targeting improvements in sleep architecture to treat neurodegenerative diseases London, UK, 7 January 2026 – AstronauTx Ltd (“AstronauTx”), a biotechnology company developing therapeutics to treat Alzheimer’s Disease and other […]
Jane Rhodes appointed as Chief Executive Officer Magnus Ivarsson appointed as Chief Translation and Early Development Officer London UK, 1 October 2024 – AstronauTx Ltd (“AstronauTx”), a biotechnology company developing novel treatments for Alzheimer’s disease and other neurodegenerative disorders, today announces the appointment of Dr Jane Rhodes, PhD, MBA, as Chief Executive Officer (CEO) and member […]
Novo Holdings, a leading life science investor, on Tuesday announced that it has led a $105 million financing in Magenta Medical, developer of the Elevate™ System, the world’s smallest heart pump. The financing will be used to advance the company’s US clinical programs in multiple mechanical circulatory support (MCS) indications and to secure the first […]
Congratulations to our clients AstronauTx and STORM Therapeutics, which were recognised at the inaugural One Nucleus Awards in London in March. AstronauTx scooped the Best Performing Primary R&D Company of the Year Award, while STORM won the One Nucleus Boston Bootcamp competition aimed at getting companies “US-ready”. AstronauTx beat off strong competition to win the […]
